Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients
Open Access
- 15 September 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Abstract
Breast cancer is the most prevalent and leading cause of mortality worldwide among women. Cell-free DNA (cfDNA) analysis is an alternative quantitative approach to conventional methods for cancer diagnosis. The current research project aimed to determine the efficacy of cfDNA as a diagnostic biomarker in breast cancer patients in Pakistan. Eighty-four female breast cancer patients were selected as cases, and 152 healthy females as controls. Immunohistochemistry was performed to identify tumor biomarkers along with clinical profiling. cfDNA was extracted from serum using the phenol–chloroform method. The cfDNA level in the serum was estimated using Agarose Gel Electrophoresis and Nanodrop. SPPS version 25.0 was used to perform statistical analyses. The results showed that the cancer biomarkers were significantly associated with breast cancer. The changes in hematological parameters were insignificant, whereas the biochemical parameter variations between the cases and controls were statistically significant. A significant association of cfDNA level with breast cancer was observed. Further cfDNA levels and cancer biomarkers were not statistically significant. A significant correlation was observed between cfDNA and biochemical parameters, except for creatinine, whereas hematological parameters showed no significant correlation.ROC analysis declared cfDNA as an authentic diagnostic marker for breast cancer. It was concluded that the level of cfDNA is significantly increased in breast cancer patients and can be utilized as a diagnostic biomarker.Keywords
This publication has 38 references indexed in Scilit:
- Cell-Free DNA as a Novel Marker in Cancer TherapyBiomarkers in Medicine, 2015
- Targeting the Androgen Receptor in Breast CancerCurrent Oncology Reports, 2015
- Unique Aspects of Caring for Young Breast Cancer PatientsCurrent Oncology Reports, 2015
- Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosisBreast Cancer Research and Treatment, 2014
- Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancerClinical Chemistry and Laboratory Medicine (CCLM), 2013
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- Circulating (cell‐free) nucleic acids – A promising, non‐invasive tool for early detection of several human diseasesFEBS Letters, 2007
- Quantification of Total Plasma Cell‐Free DNA in Ovarian Cancer Using Real‐Time PCRAnnals of the New York Academy of Sciences, 2006
- Circulating tumour‐associated plasma DNA represents an independent and informative predictor of prostate cancerBJU International, 2006